This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.

Inclusion Criteria:

• The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive disability.
• All current anti-Alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined
• Patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy.

Exclusion Criteria:

• Current diagnosis of malignancy
• Renal/liver dysfunction: Exceed two times as normal subject
• Pregnant or nursing
• Received other trial drugs within 30 days after participation of this study
• Experienced major surgery or trauma in the last 14 days